Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration

Blood

Volumn 113, Issue 23, 2009, Pages 5999-6010

  Kuns, Rachel D ^a   Morris, Edward S ^a   MacDonald, Kelli P A ^a   Markey, Kate A ^a   Morris, Helen M ^a   Raffelt, Neil C ^a   Banovic, Tatjana ^a   Don, Alistair L J ^a   Rowe, Vanessa ^a   Burman, Angela C ^a   Clouston, Andrew D ^b   Farah, Camile ^c   Besra, Gurdyal S ^d   Illarionov, Petr A ^d   Smyth, Mark J ^e   Porcelli, Steven A ^f   Hill, Geoffrey R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Envoi Pathology   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; CYTOKINE; GALACTOSYLCERAMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOMODULATION; INTERFERON PRODUCTION; INVARIANT NATURAL KILLER T CELL; LEUKEMIA CELL LINE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; CYTOKINES; FEMALE; GALACTOSYLCERAMIDES; GRAFT VS LEUKEMIA EFFECT; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67651115861     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-183335     Document Type: Article

References (30)

1. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006;107:3430-3435.
2. Morris ES, MacDonald KP, Rowe V, et al. NKT-cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005;115:3093-3103. (Pubitemid 41567574)
3. Haraguchi K, Takahashi T, Matsumoto A, et al. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol. 2005;175:1320-1328. (Pubitemid 41095022)
4. Yu KO, Im JS, Molano A, et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci U S A. 2005;102:3383-3388.
5. Morris ES, MacDonald KPA, Rowe V, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10 producing regulatory T cells and promotes transplant tolerance. Blood. 2004;103:3573-3581. (Pubitemid 38525696)
6. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213. (Pubitemid 27444217)
7. Vremec D, Pooley J, Hochrein H,Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164:2978. (Pubitemid 30148956)
8. Crowe DL, Yoon E. A common pathway for chemotherapy-induced apoptosis in human squamous cell carcinoma lines distinct from that of receptor-mediated cell death. Anticancer Res. 2003;23:2321-2328. (Pubitemid 36897098)
9. Burman AC, Banovic T, Kuns RD, et al. IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110:1064-1072. (Pubitemid 47267449)
10. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol. 2004;82:315-322. (Pubitemid 38870026)
11. Hashimoto D, Asakura S, Miyake S, et al. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol. 2005;174:551-556. (Pubitemid 40007446)
12. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol. 2007;178:6242-6251. (Pubitemid 46717407)
13. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non- Vα14Jα18 CD1d-restricted) NKT-cells suppress graft-versus-host disease by producing IFN-γ and IL-4. J Immunol. 2007;179:6579-6587.
14. Terabe M, Swann J, Ambrosino E, et al. A non-classical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005;202:1627-1633. (Pubitemid 41815868)
15. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 2007;28:491-496. (Pubitemid 350087811)
16. Ambrosino E, Terabe M, Halder RC, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol. 2007;179:5126-5136.
17. Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, Brutkiewicz RR. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer. 2006;118:3045-3053.
18. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT-cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood. 2008;111:5637-5645.
19. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004;4:231-237.
20. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202:1279-1288.
21. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med. 2002;196:119-127. (Pubitemid 34747317)
22. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100. (Pubitemid 34229476)
23. Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106:4370-4376. (Pubitemid 41775950)
24. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058-5061. (Pubitemid 46827806)
25. Schmidt CS, Mescher MF. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol. 2002;168:5521-5529.
26. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992. (Pubitemid 39273741)
27. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005;11:1244-1249. (Pubitemid 43093673)
28. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607-1618. (Pubitemid 38821994)
29. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood. 1998;91:3315-3322. (Pubitemid 28193882)
30. Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997;90:4651-4660. (Pubitemid 27508474)